Brii Biosciences

Brii Biosciences Limited (“Brii Bio”, stock code: 2137.HK) is a biotechnology company developing therapies to improve patients’ health by addressing high unmet medical needs with limited treatment options.

The Company is advancing a broad pipeline of unique therapeutic candidates with lead programs against hepatitis B virus (HBV) infection. Established in 2018 and led by a visionary and experienced leadership team, Brii Bio now has operations in both China and the United States.

On July 13, 2021, the Company was officially listed on the Hong Kong Stock Exchange under the stock code 2137.HK.